Compugen Ltd. (CGEN) 株式分析

企業概要

Compugen Ltd. is a clinical-stage therapeutic discovery and development enterprise that focuses on the research, development, and commercialization of therapeutics and product candidates across Israel, the United States, and Europe. The company operates within the healthcare sector, specifically the biotechnology industry, which implies a reliance on high-risk, high-reward scientific innovation to bring novel treatments to market. As of the latest available data, the entity holds a market capitalization of $235.53M, reported annual revenue of $72.76M, and employs approximately 75 individuals to execute its operational strategy. These valuation and revenue figures indicate that the company maintains a modest market footprint relative to large-cap peers, suggesting it is a small-cap biotechnology firm where limited financial resources are concentrated on advancing its specific pipeline programs rather than broad diversification.

財務健全性

The company reported a trailing twelve-month revenue of $72.76M, net income of $35.34M, and EBITDA of $31.80M, highlighting a significant disparity between top-line generation and bottom-line profitability. The substantial gap between revenue and net income reveals an exceptionally efficient cost structure with minimal overhead relative to sales volume, allowing the firm to retain a large portion of its earnings. Free cash flow stands at $24.33M, which provides the management with considerable financial flexibility to fund ongoing R&D expenditures or strategic acquisitions without needing immediate external capital. Profitability metrics are robust, with a gross margin of 87.3%, an operating margin of 83.2%, and a profit margin of 48.6%, indicating that the company retains the vast majority of revenue after accounting for cost of goods sold, operating expenses, and taxes. The balance sheet is highly conservative, holding $145.64M in cash against a negligible debt load of $2.96M, while the debt-to-equity ratio of 2.88 reflects a capital structure that prioritizes solvency over aggressive leverage. Liquidity is further secured by a current ratio of 6.56, demonstrating that the company possesses more than six times the current assets necessary to cover its short-term liabilities. Furthermore, the return on equity of 44.8% and return on assets of 14.4% suggest that management is utilizing shareholder capital and total assets with exceptional effectiveness to generate value.

バリュエーション評価

Valuation multiples present a complex picture, with a trailing P/E ratio of 6.53 compared to a forward P/E of -7.44, implying that the market anticipates a potential shift in earnings trajectory or accounting adjustments that will impact future profitability calculations. The price-to-book ratio of 2.28 indicates that the market is pricing the company at a premium of over double its net asset value, reflecting expectations of future growth from its pipeline. Alternative valuation metrics such as a price-to-sales ratio of 3.24 and an EV/EBITDA of 2.89 suggest the market values the company based on its sales generation and earnings power relative to enterprise value, despite the negative forward earnings expectation. The stock has traded within a 52-week range between a low of $1.13 and a high of $2.49, meaning the current trading price fluctuates significantly within this established band relative to recent historical performance. The beta value of 2.77 indicates that the stock exhibits high volatility, moving nearly three times as much as the broader market index, which necessitates a high risk tolerance for any holder of this position.

Growth & Income

Revenue growth year-over-year is reported at 4477.3%, while earnings growth is marked as N/A, indicating that the rapid expansion in sales is not yet fully reflected in reported earnings figures or that the calculation method differs due to the company's specific accounting context. Since earnings growth data is not available, it is not possible to determine if earnings are growing faster or slower than revenue using standard comparative ratios, but the massive revenue expansion signals a scaling business model. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company chooses to reinvest all generated earnings back into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is typical for early-stage or clinical-stage biotechnology firms that prioritize capital allocation toward expanding their therapeutic pipeline over providing immediate income returns. The overall growth and income profile is characterized by explosive revenue scaling and a complete absence of dividend distributions, positioning the company as a pure-play growth investment dependent on future clinical successes.